According to The Fly, credit Suisse analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN) yesterday. The company’s shares closed yesterday at $40.97, close to its 52-week high of $41.28.
Currently, the analyst consensus on AstraZeneca is a Strong Buy with an average price target of $45, representing a 9.8% upside. In a report released yesterday, BMO Capital also assigned a Buy rating to the stock with a $45 price target.
The company has a one-year high of $41.28 and a one-year low of $31.99. Currently, AstraZeneca has an average volume of 4.23M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.